José Maria Moreira

José Maria Moreira

Auto-generated profile, based on publicly available information

José Maria Moreira

Hospital da Luz Learning Health

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2019 in eLife
Verified
Journal Article
Open access
JMJosé-Maria Moreira
José-Maria Moreira
PIPavel M Itskov
Pavel M Itskov
DGDennis Goldschmidt
Dennis Goldschmidt
CBCelia Baltazar
Celia Baltazar
KSKathrin Steck
Kathrin Steck
CRCarlos Ribeiro
Carlos Ribeiro
The regulation of feeding plays a key role in determining the fitness of animals through its impact on nutrition. Elucidating the circuit basis of feeding and related behaviors is an important goal in neuroscience. We recently used a system for closed-loop optogenetic manipulation of neurons contingent on the feeding behavior of Drosophila to dissect the impact of a specific subset of taste neurons on yeast feeding. Here, we describe the development and validation of this system, which we term the optoPAD. We use the optoPAD to induce appetitive and aversive effects on feeding by activating or inhibiting gustatory neurons in closed-loop – effectively creating virtual taste realities. The use of optogenetics allowed us to vary the dynamics and probability of stimulation in single flies and assess the impact on feeding behavior quantitatively and with high throughput. These data demonstrate that the optoPAD is a powerful tool to dissect the circuit basis of feeding behavior, allowing the efficient implementation of sophisticated behavioral paradigms to study the mechanistic basis of animals’ adaptation to dynamic environments.

1 July 2022 in Radiology
Verified
Journal Article
Closed access
VKVassilis Koutoulidis
Vassilis Koutoulidis
Evangelos TerposEvangelos Terpos
Evangelos Terpos
Nikolaos PapanikolaouNikolaos Papanikolaou
Nikolaos Papanikolaou
SFSophia Fontara
Sophia Fontara
ISIOANNIS SEIMENIS
IOANNIS SEIMENIS
LMLia Angela Moulopoulos
Lia Angela Moulopoulos
Fat fraction histogram metrics had a higher performance than apparent diffusion coefficient histogram metrics at MRI examination for predicting very early (after one cycle of induction) therapy res... Background An imaging-based predictor of response could provide prognostic information early during treatment course in patients with multiple myeloma (MM). Purpose To investigate if very early cha...

23 April 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
BNBernardo Neves
Bernardo Neves
JMJosé Maria Moreira
José Maria Moreira
SGSimão Gonçalves
Simão Gonçalves
JCJorge Cerejo
Jorge Cerejo
NSNuno A. da Silva
Nuno A. da Silva
MSMário J. Silva
Mário J. Silva
Phenotyping, the process of systematically identifying and classifying conditions within clinical data, is a crucial first step in any data science work involving Electronic Health Records (EHRs). Traditional approaches require extensive manual annotation efforts and face challenges with scalability. We investigated the use of Large Language Models (LLMs) for zero-shot phenotyping of 20 prevalent chronic conditions based on synthetic patient summaries generated from real structured EHRs codes. We evaluated the performance of multiple LLMs, including GPT-4o, GPT-3.5, and LLaMA 3 models with 8-billion, 70-billion, and 405-billion parameters, comparing them against traditional rule-based methods. For the analysis we used a dataset of 1,000 patients from Hospital da Luz Lisboa. GPT-4o outperformed both traditional rule-based methods and alternative LLMs, achieving superior recall (0.97) and macro-F1 score (0.92). Rule-based phenotyping, while highly precise (0.92), showed lower recall (0.36). The integration of rule-based methods with LLMs optimized phenotyping accuracy by targeting manual annotation efforts on discordant cases. Zero-shot learning with LLMs, particularly GPT-4o, offers a powerful and efficient approach for phenotyping chronic conditions from EHRs, significantly reducing the need for extensive labeled datasets while maintaining high accuracy and interpretability.

3 October 2024 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
FFFilipa Fonseca
Filipa Fonseca
JMJ. M. Moreira
J. M. Moreira
CFC. C. Figueira
C. C. Figueira
CBC. Branco
C. Branco
Susana OurôSusana Ourô
Susana Ourô

5 March 2023 in medRxiv
Verified
Preprint
Open access
PDF file
JCJorge Cerejo
Jorge Cerejo
BNBernardo Neves
Bernardo Neves
NSNuno André da Silva
Nuno André da Silva
JMJosé Maria Moreira
José Maria Moreira
MSMário J. Silva
Mário J. Silva
In recent years, most hospitals have implemented Electronic Health Records to manage and integrate a wide range of medical information, including diagnostics, medication admission and laboratory test results. Certain laboratory variables may serve as indicators of a patient’s clinical deterioration, making laboratory data a valuable tool for identifying high-risk patients. This work introduces a framework for predicting imminent health outcomes (IHO) of multimorbidity patients using laboratory test data. Our cohort includes 322,316 multimorbidity patients that performed laboratory tests in a large teaching hospital between January 2007 and August 2021. Two Imminent Health Outcomes predictive tools were developed. The first considers all patients in the dataset. The second was developed using a subset of patients with Heart Failure (HF) as the main comorbidity (5% of the entire dataset), considering that HF is a highly prevalent syndrome in multimorbidity patients. This predictive model achieved a reasonable predictive performance ( AUROC = 0.718, 95% CI 0.708-0.756, and AUPRC = 0.663, 95% CI 0.630-0.701). C-reactive protein and NT-proBNP are the lab tests that most positively contribute to the prediction of IHO. The IHO predictive tool has the potential to help the medical team identify patients at high-risk of an imminent adverse event, highlighting the laboratory variables that are most contributing to the deterioration of the patient.

6 May 2025 in Research Square
Verified
Preprint
Open access
PDF file
BNBernardo Neves
Bernardo Neves
JMJosé M. Moreira
José M. Moreira
SGSimão Gonçalves
Simão Gonçalves
JCJorge Cerejo
Jorge Cerejo
IMInês Mota
Inês Mota
MSMário J. Silva
Mário J. Silva
Introduction : Multimorbidity is a known driver of adverse clinical outcomes and increased healthcare utilization. Although data from Electronic Health Records (EHRs) might enable risk prediction efforts, optimal multimorbidity measurement methods remain unclear. We compared multimorbidity measurement approaches to predict healthcare outcomes beyond demographics and prior healthcare utilization. Study Design and Methods : This is a retrospective cohort study using 15-year EHR data (650,651 patients, 9.4 million visits). Three phenotyping methods and five multimorbidity indices were evaluated across five outcomes and four time horizons, using logistic regression models. Best performing multimorbidity measurements were further trained with XGBoost and feature importance analysis was performed. Results : Including multimorbidity improved prediction over demographic and prior healthcare utilization features for all evaluated outcomes, particularly for rarer outcomes like inpatient mortality and unplanned admissions. Comorbidity index performance varied by outcome: Charlson Comorbidity Index was superior for mortality and readmissions, while Multimorbidity Weighted Index best predicted unplanned admissions. Clinically-curated phenotyping rules consistently outperformed standardized code-based approaches. Previous admissions and multimorbidity were top predictors of most outcomes while increased outpatient visits correlated with fewer unplanned admissions. Conclusions : Our findings show that multimorbidity measurement should be outcome-specific, with clinically-curated phenotyping methods outperforming standardized coding approaches. Healthcare systems should integrate both multimorbidity and prior utilization patterns for risk prediction models to better identify patients at highest risk for adverse outcomes.